Artelo Biosciences (ARTL) Stock Rockets 206% After Obesity Treatment Patent Filing

Key Takeaways

• Artelo Biosciences (ARTL) shares skyrocketed over 200% during Wednesday’s trading session.
• The dramatic increase followed the company’s provisional patent application for its obesity treatment candidate ART27.13.
• The patent application encompasses both standalone use and combination therapy with GLP-1 medications such as semaglutide.
• Research in mice demonstrated up to 40% body weight reduction when ART27.13 was administered alongside semaglutide.
• Despite Wednesday’s surge, ARTL shares remain 59% lower year-to-date.

Artelo Biosciences (ARTL) shares experienced a remarkable surge exceeding 200% during Wednesday’s session, reaching a peak of $12.20 before closing with approximately 206% gains. The explosive movement occurred following the clinical-stage pharmaceutical company’s announcement of a provisional patent application for its experimental compound ART27.13.

Artelo Biosciences, Inc., ARTL

The patent application encompasses ART27.13’s use as an independent obesity treatment option. Additionally, it protects the compound’s application in combination with GLP-1 receptor agonist therapies, particularly semaglutide.

This patent submission follows recent findings from the company’s DIO-2 obesity research conducted in mouse models. These latest results expand upon preliminary data initially disclosed on September 16.

Research Findings Breakdown

During the four-week study period, ART27.13 administered independently resulted in approximately 20% body weight reduction in obese mice. This outcome mirrored the weight loss achieved with semaglutide monotherapy.

The most striking results emerged from combination therapy. When scientists administered ART27.13 alongside semaglutide, test subjects experienced approximately 40% total body weight reduction. Notably, around 80% of weight loss in ART27.13-treated groups consisted of fat mass, surpassing the 70% fat mass reduction observed with semaglutide alone.

The dual therapy also enhanced glucose metabolism in test subjects. Additional benefits included appetite reduction and increased bone mineral density—a particularly significant finding given current concerns surrounding GLP-1 medications available today.

Cholesterol profiles improved across the board. Both treatments reduced total cholesterol along with LDL and HDL levels. The combination therapy generated more substantial reductions than either compound administered independently. Liver dimensions also decreased uniformly across all treatment cohorts.

Executive Commentary

Chief Executive Officer Gregory Gorgas characterized the results as surprising. He indicated these findings may significantly broaden ART27.13’s commercial potential beyond initial projections.

Gorgas emphasized the bone density improvements as particularly noteworthy. He highlighted this benefit’s relevance considering widespread pharmaceutical industry concerns regarding bone and muscle deterioration associated with conventional GLP-1 treatments.

He further noted that the compound’s dual capability—enhancing existing GLP-1 therapy while functioning as standalone treatment—creates fresh development opportunities. The organization aims to secure intellectual property protection throughout ongoing research initiatives.

ART27.13 targets two cannabinoid receptors, CB1 and CB2, positioned outside the central nervous system. Testing in lean mice revealed no significant effects on primary metabolic markers. Artelo suggests this selectivity may indicate the drug’s mechanism relates specifically to energy metabolism rather than broad pharmacological activity.

The organization has accumulated substantial human safety evidence. This database encompasses findings from six completed clinical trials, two active studies, and nearly 300 individuals who have received the experimental treatment.

Wednesday’s trading activity reflected exceptional investor interest. Over 10 million ARTL shares traded hands, dramatically exceeding the three-month daily average of approximately 95,000 shares.

However, the single-day rally hasn’t reversed longer-term losses. ARTL stock continues to trade 59% below its year-to-date opening price. Over the trailing twelve months, shares have declined 97%.

The company indicated it will pursue additional investigations to understand ART27.13’s mechanisms of action, particularly regarding fat mass reduction and bone density enhancement when combined with GLP-1 treatment protocols.

The post Artelo Biosciences (ARTL) Stock Rockets 206% After Obesity Treatment Patent Filing appeared first on Blockonomi.